Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03395340|
Recruitment Status : Recruiting
First Posted : January 10, 2018
Last Update Posted : March 18, 2019
About half the people who have a hematopoietic stem cell transplant using donor cells get cGVHD. This is chronic graft versus host disease. Immune cells from the donor may see the body tissues in the person as foreign and attack, causing damage. The skin is the most commonly affected organ. Most cGVHD therapies have serious side effects. The cream ruxolitinib inhibits proteins that may play a role in cGVHD.
To test the safety and effectiveness of topical ruxolitinib 1.5 percent cream in people with cGVHD of the skin.
People ages 12 and older with epidermal skin cGVHD
Participants will be screened with:
Blood and urine tests
Skin sample taken (biopsy) to confirm the diagnosis.
At the baseline visit, participants will have:
Skin disease measured with rulers, photographs, and tracing the outline of skin lesions
To complete questionnaires about their symptoms
Blood and urine tests
Some participants will also have a skin biopsy, or total body photographs while they wear only underwear.
Participants will get the ruxolitinib cream and a placebo cream to apply to 2 separate areas of disease. They will do this twice a day for 6 weeks, if they do not have serious side effects. Neither the study team nor the participant will know which area will get ruxolitinib cream and the placebo cream.
Participants will write down:
When they apply the creams
Any side effects
Any medications they take
Most participants will have 4 visits during the 6 weeks they use the creams. Some will have 3 visits and a phone call to see how they are doing. All participants will get a call 4-6 weeks after they stop. Visits include physical exams, blood tests, skin disease measurements, questionnaires, and photos.
|Condition or disease||Intervention/treatment||Phase|
|Graft Versus Host Disease JNS Kinase Topical Administration||Drug: Ruxolitinib 1.5% cream Drug: Vehicle cream||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Phase II Study of Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)|
|Actual Study Start Date :||November 19, 2018|
|Estimated Primary Completion Date :||October 1, 2020|
|Estimated Study Completion Date :||October 1, 2020|
|Experimental: Ruxolitinib Cream||
Drug: Ruxolitinib 1.5% cream
Ruxolitinib cream 1.5% applied as a thin film twice daily (BID)
|Placebo Comparator: Vehicle cream||
Drug: Vehicle cream
Matching vehicle cream applied as a thin film BID
- Counts of the grades of adverse events noted [ Time Frame: continuous ]CTCAE 4 will be used for grade of adverse events and each AE will bedocumented in C3D.
- Surface area measurement [ Time Frame: 6 weeks ]The surface area will be measured by tracing the lesion ontransparency paper and measuring the area from the transparency.
- Pain, pruritus, and overall severity VAS [ Time Frame: 6 weeks ]
- pharmacokinetics [ Time Frame: 2 weeks ]
- pharmacodynamics [ Time Frame: 6 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03395340
|Contact: Michelle O'Brien, R.N.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Dominique C Pichard, M.D.||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|